P01AX06 - Atovaquone |
Probably Not Porphyrinogenic |
PNP |
Rationale
Not significantly metabolised.
Chemical description
Antibiotic used in acute treatment of Pneumocystis jirovecii - pneumonia of moderate severity in patients that cannot tolerate trimethoprim/sulfamethoxazol. Administered as a oral suspension 1500mg daily for 21 days. Highly lipophilic substance with restricted bioavailability. Clinically efficient plasma concentration is 15 mg/mL. Excreted in unchanged form in stool.
Ipnet drug reports
Uneventful use reported in 4 patients with acute porphyria.
Similar drugs
Explore alternative drugs in similar therapeutic classes
References
| # | Citation details | PubMed ID |
|---|---|---|
| Porphyria Drug Lists | ||
| 1. | South African List
Porphyria South Africa No longer maintained
|
|
Tradenames
Atovaquon · Wellvone 
Wellvone 
Atovaquone · Wellvone 
Atovacuona · Wellvone 
Atovaquone · Wellvone 
Wellvone 
Atovaquone · Wellvone 
Atovaquon · Atovaquone 
Atovaquone · Wellvone 
Wellvone 
Promozio · Wellvone 
Atovaquone · Mepron 
Wellvone 
Atovacuona · Wellvone 
Atovaquone · Atovaquone component of malarone · Mepron · Wellvone 
Atovacuona 
Atovaquone